Farmakoterapia bezdechu u wcześniaczej subpopulacji neonatologicznej– możliwości terapeutyczne, implikacje farmakokinetyczne i wskazania do terapeutycznego monitorowania stężeniem leku we krwi

Bartłomiej Kot; Mateusz Moczulski; Agnieszka Czajkowska; Arkadiusz Kocur

doi:10.56782/pps.186

Published : 2024-05-08

Vol. 22 No. 2 (2024)

Pharmacotherapy of apnea in the premature neonatological subpopulation – therapeutic opportunities, pharmacokinetic implications and recommendations for therapeutic drug monitoring

Bartłomiej Kot

Mateusz Moczulski

Agnieszka Czajkowska

Arkadiusz Kocur

DOI: https://doi.org/10.56782/pps.186

Abstract

Apnea of prematurity (AOP) is a relatively common health problem among neonatal patients born prematurely. It involves stopping breathing, which is dangerous to a child's health and life. In addition to the classic non-pharmacological methods, apnea episodes are treated with methylxanthines and/or doxapram. The gold standard treatment for AOP is caffeine citrate, which has a more favourable safety profile than theophylline or the second-line drug, doxapram. Despite their obvious therapeutic benefits, methylxanthines have specific pharmacokinetics in newborns. In this group, pharmacotherapy requires particular individualization of drug dosing due to differences in the stage of metabolism and excretion of drugs from the body. The following mini-review of the literature aimed to characterise the therapeutic possibilities of AOP treatment using instrumental and pharmacological methods. Particular attention was paid to the pharmacokinetics of the drugs used and the individualisation of therapy based on therapy monitored by drug concentration in the blood. Toxic side effects, as well as the specificity of the interactions of methylxanthines and doxapram with other drugs, have been discussed. Additionally, attention has been drawn to the need to introduce the possibility of monitoring the concentrations of methylxanthines (in particular, caffeine citrate) in routine clinical practice. Unfortunately, currently, monitoring of pharmacological treatment for apnea in premature infants is based on instrumented methods and strict clinical observation of the patient under the supervision of an experienced doctor specialising in neonatology.

Keywords:

caffeine citrate, theophylline, doxapram, apnea of prematurity

Most read articles by the same author(s)

Aleksandra Mikulska, Arkadiusz Kocur, Pharmacotherapy with high doses of methotrexate (HDMTX) in oncology – how should chemotherapy be conducted based on therapeutic drug monitoring? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 4 (2023)
Arkadiusz Kocur, Dorota Marszałek, Tomasz Pawiński, USE OF CHROMATOGRAPHIC METHODS FOR INOSINE DEHYDROGENASE ACTIVITY DETERMINATION (IMPDH) IN IMMUNOSUPPRESSIVE THERAPY , Prospects in Pharmaceutical Sciences: Vol. 18 No. 5 (2020)

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Kot, B., Moczulski, M., Czajkowska, A., & Kocur, A. (2024). Pharmacotherapy of apnea in the premature neonatological subpopulation – therapeutic opportunities, pharmacokinetic implications and recommendations for therapeutic drug monitoring. Prospects in Pharmaceutical Sciences, 22(2), 30–38. https://doi.org/10.56782/pps.186

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Vachharajani, A.; Dawson, J. Respiratory disorders in the neonate. In Biochemical and Molecular Basis of Pediatric Disease;Academic Press: London, Great Britain, 2021, pp. 117-130.doi.org/10.1016/B978-0-12-817962-8.00004-4 DOI: https://doi.org/10.1016/B978-0-12-817962-8.00004-4

Szczapa, J.; Szczapa T. Choroby układu oddechowego. In Podstawy neonatologii; Wydawnictwo Lekarskie PZWL: Warszawa, Poland, 2008, pp. 165-167.

Martin, R.J.; Abu-Shaweesh, J.M.; Baird, T.M. Apnoea of prematurity. Paediatr Respir Rev. 2004,5, Suppl A:S377-382. doi: 10.1016/s1526-0542(04)90067-x. DOI: https://doi.org/10.1016/S1526-0542(04)90067-X

Zhao, J.; Gonzalez, F.; Mu, D. Apnea of prematurity: from cause to treatment. Eur J Pediatr. 2011,170(9),1097-1105. doi: 10.1007/s00431-011-1409-6 DOI: https://doi.org/10.1007/s00431-011-1409-6

Martin, R.J.; Fanaroff, A.A. Neonatal apnea, bradycardia, or desaturation: does it matter? J Pediatr. 1998,132(5), 758-759. doi: 10.1016/s0022-3476(98)70297-5. DOI: https://doi.org/10.1016/S0022-3476(98)70297-5

Poets, C.F. Apnea of prematurity: What can observational studies tell us about pathophysiology? Sleep Med. 2010, 11(7), 701-707. doi: 10.1016/j.sleep.2009.11.016. DOI: https://doi.org/10.1016/j.sleep.2009.11.016

Jones, R.A.; Lukeman, D. Apnoea of immaturity. Mortality and handicap. Arch Dis Child. 1982, 57(10), 766-768. doi: 10.1136/adc.57.10.766. DOI: https://doi.org/10.1136/adc.57.10.766

Janvier, A.; Khairy, M.; Kokkotis, A.; Cormier, C.; Messmer, D.; Barrington, K.J. Apnea is associated with neurodevelopmental impairment in very low birth weight infants. J Perinatol. 2004, 24(12), 763-768. doi: 10.1038/sj.jp.7211182. DOI: https://doi.org/10.1038/sj.jp.7211182

Di Fiore, J.M.; Kaffashi, F.; Loparo, K.; Sattar, A.; Schluchter, M.; Foglyano, R.; Martin, R.J., Wilson, C.G. The relationship between patterns of intermittent hypoxia and retinopathy of prematurity in preterm infants. Pediatr Res. 2012, 72(6), 606-612. doi: 10.1038/pr.2012.132. DOI: https://doi.org/10.1038/pr.2012.132

Williamson, M.; Poorun, R.; Hartley, C. Apnoea of Prematurity and Neurodevelopmental Outcomes: Current Understanding and Future Prospects for Research. Front Pediatr. 2021,25(9),755-677. doi: 10.3389/fped.2021.755677. DOI: https://doi.org/10.3389/fped.2021.755677

Pergolizzi, J.; Kraus, A.; Magnusson, P.; Breve, F.; Mitchell, K.; Raffa, R.; LeQuang, J.A.K.; Varrassi, G. Treating Apnea of Prematurity. Cureus. 2022, 14(1),217-283. doi: 10.7759/cureus.21783 DOI: https://doi.org/10.7759/cureus.21783

Abu-Shaweesh, J.M., Martin, R.J. Neonatal apnea: what's new? Pediatr Pulmonol. 2008, 43(10), 937-944. doi: 10.1002/ppul.20832. DOI: https://doi.org/10.1002/ppul.20832

Bober, K.; Swietliński, J.; Musialik-Swietlińska, E.; Łaniewski-Wołłk, P.; Rawicz, M. Zasady uwalniania noworodków z wentylacji neinwazyjnej [Weaning newborns from noninvasive ventilation. Med Wieku Rozwoj. 2008,12,865-868. Polish.

Moretti, C.; Gizzi, C.; Papoff, P.; Lampariello, S.; Capoferri, M.; Calcagnini, G.; Bucci, G. Comparing the effects of nasal synchronized intermittent positive pressure ventilation (nSIPPV) and nasal continuous positive airway pressure (nCPAP) after extubation in very low birth weight infants. Early Hum Dev. 1999,56(2-3),167-177. doi: 10.1016/s0378-3782(99)00046-8. DOI: https://doi.org/10.1016/S0378-3782(99)00046-8

Aldana-Aguirre, J.C.; Pinto, M.; Featherstone, R.M.; Kumar, M. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2017, 102(1), 17-23. doi: 10.1136/archdischild-2015-310299. DOI: https://doi.org/10.1136/archdischild-2015-310299

Smith, V.C.; Kelty-Stephen, D.; Qureshi Ahmad, M.; Mao, W.; Cakert, K; Osborne, J; Paydarfar, D. Stochastic Resonance Effects on Apnea, Bradycardia, and Oxygenation: A Randomized Controlled Trial. Pediatrics. 2015,136(6),1561-1568. doi: 10.1542/peds.2015-1334. DOI: https://doi.org/10.1542/peds.2015-1334

Smit, J.P.; Hagen, E.J. Polymorphism in Caffeine Citric Acid Cocrystals. J Chem Crystallogr. 2015, 45, 128–133. https://doi.org/10.1007/s10870-015-0573-3 DOI: https://doi.org/10.1007/s10870-015-0573-3

National Center for Biotechnology Information. "PubChem Compound Summary for CID 6241, Caffeine Citrate" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Caffeine-Citrate. Accessed 23 December, 2023.

National Center for Biotechnology Information. "PubChem Compound Summary for CID 2153, Theophylline" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Theophylline. Accessed 24 December, 2023.

Armanian, A.M.; Badiee, Z.; Afghari, R.; Salehimehr, N.; Hassanzade, A.; Sheikhzadeh, S.; Sharif Tehrani, M.; Rezvan, G. Prophylactic aminophylline for prevention of apnea at higher-risk preterm neonates. Iran Red Crescent Med J. 2014,16(8), 125-159. doi: 10.5812/ircmj.12559. DOI: https://doi.org/10.5812/ircmj.12559

National Center for Biotechnology Information. "PubChem Compound Summary for CID 3156, Doxapram" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Doxapram. Accessed 24 December, 2023.

Katzung, B.G., Masters, S.B., Trevor, A.J. Drugs with important actions on smooth muscle. In Basic and Clinical Pharmacology, 12th Edition; The McGraw-Hill Companies: London, Great Britain 2012; 344-346.

Aranda, J.V.; Beharry, K.D. Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns. Semin Fetal Neonatal Med. 2020, 25(6), 1011-10083. doi: 10.1016/j.siny.2020.101183. DOI: https://doi.org/10.1016/j.siny.2020.101183

Mutschler, E. Farmakologia szczegółowa. In Farmakologia i Toksykologia, MedPharm:Wrocław, Polska, 2010; 195-196 and651-652.

Bruschettini, M.; Brattström, P.; Russo, C.; Onland, W.; Davis, P.G.; Soll, R. Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity. Cochrane Database Syst Rev. 2023, 4(4), 138-173. doi: 10.1002/14651858.CD013873.pub2. DOI: https://doi.org/10.1002/14651858.CD013873.pub2

Hascoet, J.M.; Hamon, I.; Boutroy, M.J. Risks and benefits of therapies for apnoea in premature infants. Drug Saf. 2000, 23(5), 363-79. doi: 10.2165/00002018-200023050-00002. DOI: https://doi.org/10.2165/00002018-200023050-00002

Yost, C.S. A new look at the respiratory stimulant doxapram. CNS Drug Rev. 2006, 12(3-4), 236-249. doi: 10.1111/j.1527-3458.2006.00236.x. DOI: https://doi.org/10.1111/j.1527-3458.2006.00236.x

Cunningham, K.P.; MacIntyre, D.E.; Mathie, A.; Veale, E.L. Effects of the ventilatory stimulant, doxapram on human TASK-3 (KCNK9, K2P9.1) channels and TASK-1 (KCNK3, K2P3.1) channels. Acta Physiol (Oxf). 2020,228(2), 133-161. doi: 10.1111/apha.13361. DOI: https://doi.org/10.1111/apha.13361

Greze, E.; Benard, M.; Hamon, I.; Casper, C.; Haddad, F.E.; Boutroy, M.J.; Hascoët, J.M. Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial. Paediatr Drugs. 2016,18(6), 443-449. doi: 10.1007/s40272-016-0192-2. DOI: https://doi.org/10.1007/s40272-016-0192-2

Barbé, F.; Hansen, C.; Badonnel, Y.; Legagneur, H.; Vert, P.; Boutroy, M.J. Severe side effects and drug plasma concentrations in preterm infants treated with doxapram. Ther Drug Monit. 1999,21(5), 547-552. doi: 10.1097/00007691-199910000-00011 DOI: https://doi.org/10.1097/00007691-199910000-00011

Charakterystyka Produktu Leczniczego Peyona, https://ec.europa.eu/health/documents/community-register/2016/20160224134299/anx_134299_pl.pdf. Accessed 16 February, 2024.

Aranda, J.V.; Turmen, T.; Sasyniuk, B.I. Pharmacokinetics of diuretics and methylxanthines in the neonate. Eur J Clin Pharmacol. 1980,18(1), 55-63. doi: 10.1007/BF00561479. DOI: https://doi.org/10.1007/BF00561479

Adamska-Dyniewska, H. Teofilina In Terapia monitorowana Wydawnictwo TTM:Łódź, Polska 1994, 68-79

Flint, R.B.; Simons, S.H.P.; Andriessen, P.; Liem, K.D.; Degraeuwe, P.L.J.; Reiss, I.K.M.; Ter Heine, R.; Engbers, A.G.J.; Koch, B.C.P.; Groot, R.; Burger, D.M.; Knibbe, C.A.J.; Völler, S. DINO Research Group. The bioavailability and maturing clearance of doxapram in preterm infants. Pediatr Res. 2021, 89(5), 1268-1277. doi: 10.1038/s41390-020-1037-9. DOI: https://doi.org/10.1038/s41390-020-1037-9

Lopez-Sanchez, R.D.C.; Lara-Diaz, V.J.; Aranda-Gutierrez, A.; Martinez-Cardona, J.A.; Hernandez, J.A. HPLC Method for Quantification of Caffeine and Its Three Major Metabolites in Human Plasma Using Fetal Bovine Serum Matrix to Evaluate Prenatal Drug Exposure. J Anal Methods Chem. 2018, 208, 50-59. doi: 10.1155/2018/2085059. DOI: https://doi.org/10.1155/2018/2085059

Routledge, P.A.; Hutchings, A. Therapeutic drug monitoring. TDM. 2013, 945-962. DOI: https://doi.org/10.1016/B978-0-08-097037-0.00076-2

Long, J.Y.; Hu, Y.H.; Xia, Y.; Du, F.F.; Dai, H.R.; Tian, M.; Xu, J.; Cheng, R.; Ding, X.S.; Guo, H.L.; Chen, F. Therapeutic drug monitoring of caffeine and its primary metabolites in plasma using LC-ESI-MS/MS for apnea of prematurity treatment: Evaluation of ultrapure water as a surrogate matrix. Biomed Chromatogr. 2022, 36(11),54-62. doi: 10.1002/bmc.5462. DOI: https://doi.org/10.1002/bmc.5462

Pesce, A.J.; Rashkin, M.; Kotagal, U. Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry. Clin Chem. 1998, 44(5), 1124-1128.

Juárez-Olguín, H. Therapeutic monitoring of theophylline in newborns with apnea.P&T.2004, 29, 322-324.

Bartłomiej Kot

bartekkot2001@wp.pl

Affiliation:

Students Scientific Association ‘’DRUG’’, Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, 02-091 Warsaw, Poland. Poland

Mateusz Moczulski

mmoczulski8@gmail.com

Affiliation:

Agnieszka Czajkowska

a.czajkowska@ipczd.pl

Affiliation:

Therapeutic Drug Monitoring, Clinical Pharmacokinetics and Toxicology Laboratory Unit, Department of Clinical Biochemistry, The Children’s Memorial Health Institute, 04-730 Warsaw, Poland Poland

Arkadiusz Kocur

arkadiusz.kocur@wum.edu.pl

Affiliation:

Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, 02-091 Warsaw, Poland. Poland